
The article discusses the results of a phase 3 trial of a single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) conducted in Russia. The trial involved 496 participants, and the vaccine demonstrated a marked immune response with elevated levels of antibodies against the S protein and receptor binding domain (RBD) of SARS-CoV-2. The vaccine also induced a robust cellular immune response, and the primary and secondary endpoints were statistically significant compared to the placebo. The vaccine had a favorable safety profile, with generally mild and resolved adverse reactions reported. Overall, the study concludes that Ad5-nCoV is effective and safe as a single-dose COVID-19 vaccine.
Like
Save
Share